The present study aimed at formulation of enteric coated tablets of pantoprazole and to assess the influence of appropriate additives on the performance of the final product The influence of different diluents disintegrants and binders upon the precompression characters and physico-chemical properties of the tablets were studied and an optimized formulation with passable quality was selected Shirsand et al have designed fast dissolving tablets of Clonazepam6 with the help of sodium starch glyconate crospovidone croscarmellose as disintegrating agents in different ratios with microcrystalline cellulose by direct compression technique from the above study they concluded that formulation prepared by using 10 percent w/w of crospovidone and 35 percent w/w of microcrystalline

Sustained release enteric coated tablets of pantoprazole

Sustained release enteric coated tablets of pantoprazole: formulation in vitro and in vivo evaluation Acta Pharm 2013 63(1):131-40 (ISSN: 1846-9558) Wilson B Babubhai PP Sajeev MS Jenita JL Priyadarshini SR In this study an attempt was made to deliver pantoprazole in a sustained manner using delayed release tablets The tablets were prepared by the wet granulation method using HPMC

Objective: To investigate the preparation and stability of (l) -pantoprazole sodium enteric tablets Methods:The formulation of (l)-pantoprazole sodium enteric tablets was optimized by an orthogonal design involved in 3 factors and 3 levels [quantity of sodium carbonate (0 5% 10% ) types of binders(MC HPMC PVP) and concentration of binders(2% 5% 8% ) ]

The study medications of pantoprazole (40 mg) and matching placebo were prepared by Pharmaceutical Packaging Professionals (Victoria Australia) on the advice of the clinical pharmacologist from RAH The pantoprazole (commercial product) pills were de-blistered and placed into an empty gelatine capsule and then filled with lactose or other inert filler to disguise their content The placebo

2 2 Study Drugs The reference product was commercially available 40 mg pantoprazole sodium enteric-coated tablets Pantocid manufactured by Sun Pharma Mumbai India (lot no BSK0980 Mfd 04/2011 Exp 03/2014) Test product was formulated as 1: 2 mixture of pantoprazole sodium with HPBCD enteric-coated tablets Tripepsa manufactured by Akums Drugs Pharmaceuticals Limited India (lot no

Formulation Development and Evaluation of Enteric Coated Tablets of Rabeprazole Sodium B Rama* Shalem Raju Talluri Grace Rathnam Department of Pharmaceutics C L Baid Metha College Of Pharmacy Chennai Abstract: Rabeprazole sodium is highly acid-labile and presents many formulation challenges and to protect it from acidic environment of the stomach an enteric coated tablet formulation

Pharmacokinetics and pharmacodynamics of

Objective : To investigate the pharmacokinetics and pharmacodynamics of pantoprazole following i v or intragastric administration in healthy neonatal foals Methods : Seven healthy foals age 6–12 days at the start of the study were evaluated Treatments included no drug administration i v pantoprazole (1 5 mg/kg bwt) and intragastric

Objective : To investigate the pharmacokinetics and pharmacodynamics of pantoprazole following i v or intragastric administration in healthy neonatal foals Methods : Seven healthy foals age 6–12 days at the start of the study were evaluated Treatments included no drug administration i v pantoprazole (1 5 mg/kg bwt) and intragastric

16/06/2005Pantoprazole sodium multiparticulates are described which avoid sticking to nasogastric and gastronomy tubes The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof or a salt thereof a surfactant and a distintegrant a sub coat which is comprised of hydroxypropyl methylcellulose (hypromellose) and water an enteric coat on the sub-coat and a final

2 4 STUDY DESIGN The dose of pantoprazole to rat was 20 mg/kg 10 tablets of pantop/pantocid which contain 40 mg dose of pantoprazole was crushed and weight equivalent to 40 mg was dissolved in a 5 mL volumetric flask with sufficient water The volumetric flask was made up with water According to their body weight of each animal dose (20 mg/kg) of the solution was given through oral gavage

Pantoprazole is a category of proton pump inhibitor belongs to group of benzimidazole derivative used for the treatment of gastric and duodenal ulcers Pantoprazole is undergoes degradation in acidic media of stomach In the present study was attempted to formulate and evaluate pantoprazole sodium as enteric coated tablet The pre-compression parameter of blend was performed includes FT-IR

Formulation and Evaluation of Delayed Release Pantoprazole Tablets Pantoprazole is a proton pump inhibitor belongs to group of benzimidazole used for the treatment of gastric and duodenum ulcers Pantoprazole undergoes degradation in acid medium of the stomach can be coated with enteric coating polymer that will safely deliver the drug in the small intestine In this present study an

In a 5-day study of oral pantoprazole with 40 and 60 mg doses in healthy subjects following the last dose on day 5 median 24-hour serum gastrin concentrations were elevated by 3-4 fold compared to placebo in both 40 and 60 mg dose groups However by 24 hours following the last dose median serum gastrin concentrations for both groups returned to normal levels In another placebo-controlled

US7550153B2 US11/731 474 US73147407A US7550153B2 US 7550153 B2 US7550153 B2 US 7550153B2 US 73147407 A US73147407 A US 73147407A US 7550153 B2 US7550153 B2 US 7550153B2 Authority US United States Prior art keywords multiparticulates method according pantoprazole mg coat Prior art date 2003-10-01 Legal status (The legal status is an assumption and is

Formulation and In

Pantoprazole is a category of proton pump inhibitor belongs to group of benzimidazole derivative used for the treatment of gastric and duodenal ulcers Pantoprazole is undergoes degradation in acidic media of stomach In the present study was attempted to formulate and evaluate pantoprazole sodium as enteric coated tablet The pre-compression parameter of blend was performed includes FT-IR

A new oral formulation pantoprazole sodium dela-yed-release granules for oral suspension has been developed to allow for the oral or nasogastric (NG) tube administration of 40 mg of pantoprazole to adult patients when they cannot swallow tablets and intra-venous pantoprazole may not be practical This formu-lation may be orally administered to adults by three methods: (i) oral administration

FORMULATION AND EVALUATION OF ORAL DISINTEGRATING TABLETS OF PANTOPRAZOLE INTRODUCTION: In this present study an effort has been made to formulate fast disintegrating and rapid release tablets also called as Oral disintegrating tablets of Pantoprazole using four different Superdisintegrants like Croscarmellose sodium Sodium starch glycolate (SSG) Micro crystalline

The objective of this study was to investigate the bioequivalence of two formulations of 40 mg pantoprazole sodium enteric-coated tablets: Tripepsa as the test and Pantocid as the reference The two products were administered as a single oral dose according to a randomized two-phase crossover with a 1-month washout period in 25 healthy Indian volunteers After drug administration serial blood

This crossover study analysed the effect of pantoprazole on MMF and EC‐MPS pharmacokinetics in renal transplant patients under maintenance immunosuppressive therapy For pantoprazole intake bioequivalence was not established for either MMF or EC‐MPS Further analysis showed no impact of pantoprazole on MPAG pharmacokinetics or MPA pharmacodynamics Introduction Mycophenolic

The invention relates to new formulations and dosage units of solid crystalline pantoprazole free acid and its salts (e g pantoprazole sodium sesquihydrate) that are resistant to gastric juice digestion and are useful for the therapeutic treatment (including prophylactic treatment) of mammals including humans and a process for making the same

PANTOPRAZOLE SANDOZ 40 mg comprim gastro-rsistant est indiqu chez les adultes et les adolescents gs de 12 ans et plus pour : l'oesophagite par reflux gastro-oesophagien PANTOPRAZOLE SANDOZ 40 mg comprim gastro-rsistant est indiqu chez les adultes pour : l'ulcre gastrique et duodnal le syndrome de Zollinger-Ellison et autres situations hyperscrtoires

Study selection: Clinical Pantoprazole which is in the final stages of approval for marketing in the United States will be available in both an oral and injectable formulation Conclusion: Based on superior efficacy profiles PPIs are the drugs of choice in managing patients with peptic ulcer disease gastroesophageal reflux disease and Zollinger-Ellison syndrome The decision to select